Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?
Theravance Biopharma reported Q2 2026 earnings matching estimates with revenues of $20.7 million, marginally beating consensus. The stock has gained 0.8% since the earnings report. The company achieved profitability with adjusted EPS of 19 cents versus a loss a year ago, driven by Yupelri collaboration revenues and significant cost-cutting measures. However, analysts remain quiet with no estimate revisions, and the stock carries a Zacks Rank #3 (Hold) rating with poor growth and momentum scores.